180 related articles for article (PubMed ID: 32873863)
21. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
[TBL] [Abstract][Full Text] [Related]
22. Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy.
Wu X; Scott H; Carlsson SV; Sjoberg DD; Cerundolo L; Lilja H; Prevo R; Rieunier G; Macaulay V; Higgins GS; Verrill CL; Lamb AD; Cunliffe VT; Bountra C; Hamdy FC; Bryant RJ
Prostate; 2019 Jul; 79(10):1079-1089. PubMed ID: 31104332
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of tissue and circulating levels of IMP3 in prostate cancer.
Szarvas T; Tschirdewahn S; Niedworok C; Kramer G; Sevcenco S; Reis H; Shariat SF; Rübben H; vom Dorp F
Int J Cancer; 2014 Oct; 135(7):1596-604. PubMed ID: 24615121
[TBL] [Abstract][Full Text] [Related]
24. Conditionally replicative adenovirus carrying shRNA targeting EZH2 inhibits prostate cancer growth and invasion.
Xu SG; Yu JJ; Shi Q; Niu Q; Guo Z; Guo BY; Zhou GC; Gu X; Wu YX
Oncol Rep; 2019 Jul; 42(1):273-282. PubMed ID: 31115564
[TBL] [Abstract][Full Text] [Related]
25. PTPIP51 mRNA and protein expression in tissue microarrays and promoter methylation of benign prostate hyperplasia and prostate carcinoma.
Koch P; Petri M; Paradowska A; Stenzinger A; Sturm K; Steger K; Wimmer M
Prostate; 2009 Dec; 69(16):1751-62. PubMed ID: 19691131
[TBL] [Abstract][Full Text] [Related]
26. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer.
Enokida H; Shiina H; Igawa M; Ogishima T; Kawakami T; Bassett WW; Anast JW; Li LC; Urakami S; Terashima M; Verma M; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Cancer Res; 2004 Sep; 64(17):5956-62. PubMed ID: 15342374
[TBL] [Abstract][Full Text] [Related]
27. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer.
Tokizane T; Shiina H; Igawa M; Enokida H; Urakami S; Kawakami T; Ogishima T; Okino ST; Li LC; Tanaka Y; Nonomura N; Okuyama A; Dahiya R
Clin Cancer Res; 2005 Aug; 11(16):5793-801. PubMed ID: 16115918
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of N-myc downstream-regulated gene 2 in prostatic carcinoma.
Yu C; Wu G; Dang N; Zhang W; Zhang R; Yan W; Zhao Y; Gao L; Wang Y; Beckwith N; Yuan J; Yao L
Cancer Biol Ther; 2011 Aug; 12(4):304-13. PubMed ID: 21623166
[TBL] [Abstract][Full Text] [Related]
30. LncRNA MEG3 inhibits the progression of prostate cancer by facilitating H3K27 trimethylation of EN2 through binding to EZH2.
Zhou Y; Yang H; Xia W; Cui L; Xu R; Lu H; Xue D; Tian Z; Ding T; Cao Y; Shi Q; He X
J Biochem; 2020 Mar; 167(3):295-301. PubMed ID: 31790140
[TBL] [Abstract][Full Text] [Related]
31. Rottlerin inhibits cell growth and invasion via down-regulation of EZH2 in prostate cancer.
Zheng N; Wang L; Hou Y; Zhou X; He Y; Wang Z
Cell Cycle; 2018; 17(21-22):2460-2473. PubMed ID: 30394832
[TBL] [Abstract][Full Text] [Related]
32. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer.
Ma L; Yan Y; Bai Y; Yang Y; Pan Y; Gang X; Karnes RJ; Zhang J; Lv Q; Wu Q; Huang H
Theranostics; 2019; 9(17):5020-5034. PubMed ID: 31410199
[No Abstract] [Full Text] [Related]
33. Integrative bioinformatics links HNF1B with clear cell carcinoma and tumor-associated thrombosis.
Cuff J; Salari K; Clarke N; Esheba GE; Forster AD; Huang S; West RB; Higgins JP; Longacre TA; Pollack JR
PLoS One; 2013; 8(9):e74562. PubMed ID: 24040285
[TBL] [Abstract][Full Text] [Related]
34. Genome-wide ChIP-seq analysis of EZH2-mediated H3K27me3 target gene profile highlights differences between low- and high-grade astrocytic tumors.
Sharma V; Malgulwar PB; Purkait S; Patil V; Pathak P; Agrawal R; Kulshreshtha R; Mallick S; Julka PK; Suri A; Sharma BS; Suri V; Sharma MC; Sarkar C
Carcinogenesis; 2017 Feb; 38(2):152-161. PubMed ID: 27993893
[TBL] [Abstract][Full Text] [Related]
35. Methylation-dependent and -independent roles of EZH2 synergize in CDCA8 activation in prostate cancer.
Yi Y; Li Y; Li C; Wu L; Zhao D; Li F; Fazli L; Wang R; Wang L; Dong X; Zhao W; Chen K; Cao Q
Oncogene; 2022 Mar; 41(11):1610-1621. PubMed ID: 35094010
[TBL] [Abstract][Full Text] [Related]
36. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.
Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B
Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612
[TBL] [Abstract][Full Text] [Related]
37. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
Ogishima T; Shiina H; Breault JE; Tabatabai L; Bassett WW; Enokida H; Li LC; Kawakami T; Urakami S; Ribeiro-Filho LA; Terashima M; Fujime M; Igawa M; Dahiya R
Clin Cancer Res; 2005 Feb; 11(3):1028-36. PubMed ID: 15709168
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.
Nørgaard M; Haldrup C; Storebjerg TM; Vestergaard EM; Wild PJ; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28930171
[TBL] [Abstract][Full Text] [Related]
39. Molecular and Clinicopathological Aspects of Prostate Cancer in Bulgarian Probands.
Tsvetkova A; Todorova A; Todorov T; Georgiev G; Drandarska I; Mitev V
Pathol Oncol Res; 2015 Sep; 21(4):969-76. PubMed ID: 25753984
[TBL] [Abstract][Full Text] [Related]
40. EZH2 polycomb transcriptional repressor expression correlates with methylation of the APAF-1 gene in superficial transitional cell carcinoma of the bladder.
Hinz S; Kempkensteffen C; Weikert S; Schostak M; Schrader M; Miller K; Christoph F
Tumour Biol; 2007; 28(3):151-7. PubMed ID: 17541304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
